Search Results - "Bates, Breanna"

Accumulation of long-chain fatty acids in the tumor microenvironment drives dysfunction in intrapancreatic CD8+ T cells by Manzo, Teresa, Prentice, Boone M, Anderson, Kristin G, Raman, Ayush, Schalck, Aislyn, Codreanu, Gabriela S, Nava Lauson, Carina B, Tiberti, Silvia, Raimondi, Andrea, Jones, Marissa A, Reyzer, Michelle, Bates, Breanna M, Spraggins, Jeffrey M, Patterson, Nathan H, McLean, John A, Rai, Kunal, Tacchetti, Carlo, Tucci, Sara, Wargo, Jennifer A, Rodighiero, Simona, Clise-Dwyer, Karen, Sherrod, Stacy D, Kim, Michael, Navin, Nicholas E, Caprioli, Richard M, Greenberg, Philip D, Draetta, Giulio, Nezi, Luigi

“…CD8+ T cells are master effectors of antitumor immunity, and their presence at tumor sites correlates with favorable outcomes. However, metabolic constraints…”
Get full text

A Fas-4-1BB fusion protein converts a death to a pro-survival signal and enhances T cell therapy by Oda, Shannon K, Anderson, Kristin G, Ravikumar, Pranali, Bonson, Patrick, Garcia, Nicolas M, Jenkins, Cody M, Zhuang, Summer, Daman, Andrew W, Chiu, Edison Y, Bates, Breanna M, Greenberg, Philip D

“…Adoptive T cell therapy (ACT) with genetically modified T cells has shown impressive results against some hematologic cancers, but efficacy in solid tumors can…”
Get full text

Small Cell Lung Cancer Exhibits Frequent Inactivating Mutations in the Histone Methyltransferase KMT2D/MLL2: CALGB 151111 (Alliance) by Augert, Arnaud, Zhang, Qing, Bates, Breanna, Cui, Min, Wang, Xiaofei, Wildey, Gary, Dowlati, Afshin, MacPherson, David

“…SCLC is a lethal neuroendocrine tumor type that is highly prone to metastasis. There is an urgency to understand the mutated genes that promote SCLC, as there…”
Get more information

Development of a clinically relevant ovarian cancer model incorporating surgical cytoreduction to evaluate treatment of micro-metastatic disease by Morse, Christopher B., Voillet, Valentin, Bates, Breanna M., Chiu, Edison Y., Garcia, Nicolas M., Gottardo, Raphael, Greenberg, Philip D., Anderson, Kristin G.

“…Mouse models of ovarian cancer commonly transfer large numbers of tumor cells into the peritoneal cavity to establish experimental metastatic disease, which…”
Get full text

Engineering adoptive T cell therapy to co-opt Fas ligand-mediated death signaling in ovarian cancer enhances therapeutic efficacy by Anderson, Kristin G, Oda, Shannon K, Bates, Breanna M, Burnett, Madison G, Rodgers Suarez, Magdalia, Ruskin, Susan L, Greenberg, Philip D

“…BackgroundIn the USA, more than 50% of patients with ovarian cancer die within 5 years of diagnosis, highlighting the need for therapeutic innovations…”
Get full text

Engineered Adoptive T-cell Therapy Prolongs Survival in a Preclinical Model of Advanced-Stage Ovarian Cancer by Anderson, Kristin G, Voillet, Valentin, Bates, Breanna M, Chiu, Edison Y, Burnett, Madison G, Garcia, Nicolas M, Oda, Shannon K, Morse, Christopher B, Stromnes, Ingunn M, Drescher, Charles W, Gottardo, Raphael, Greenberg, Philip D

“…Adoptive T-cell therapy using high-affinity T-cell receptors (TCR) to target tumor antigens has potential for improving outcomes in high-grade serous ovarian…”
Get more information

803 Triple checkpoint blockade, but not anti-PD1 alone, enhances the efficacy of engineered adoptive T cell therapy in advanced ovarian cancer by Anderson, Kristin G, Su, Yapeng, Burnett, Madison G, Bates, Breanna M, Suarez Gutierrez, Magdalia L, Ruskin, Susan L, Voillet, Valentin, Gottardo, Raphael, Greenberg, Philip D

“…BackgroundOver 20,000 women are diagnosed with ovarian cancer annually, and more than half will die within 5 years. This rate has changed little in the last 30…”
Get full text

A mouse model of MYCN-driven retinoblastoma reveals MYCN-independent tumor reemergence by Wu, Nan, Jia, Deshui, Bates, Breanna, Basom, Ryan, Eberhart, Charles G, MacPherson, David

“…The most frequent focal alterations in human retinoblastoma are mutations in the tumor-suppressor gene retinoblastoma (RB) and amplification of the oncogene…”
Get full text

Triple checkpoint blockade, but not anti-PD1 alone, enhances the efficacy of engineered adoptive T cell therapy in advanced ovarian cancer by Anderson, Kristin G, Su, Yapeng, Burnett, Madison, Bates, Breanna, Suarez, Magdalia Rodgers, Voillet, Valentin, Gottardo, Raphael, Greenberg, Philip D

“…Less than 50% of ovarian cancer patients survive five years after diagnosis. This rate has changed little in the last 30 years, highlighting the need for novel…”
Get full text

Abstract 2555: Engineering adoptive T cell therapy to co-opt Fas ligand-mediated death signaling in solid tumors by Anderson, Kristin, Oda, Shannon, Bates, Breanna, Chiu, Edison, Morse, Christopher, Garcia, Nicolas, Greenberg, Philip

“…Over 20,000 women are diagnosed with ovarian cancer annually, and over half will die within 5 years. This rate has changed little in the last 20 years,…”
Get full text

Engineering adoptive T cell therapy to co-opt Fas ligand-mediated death signaling in solid tumors by Anderson, Kristin G, Oda, Shannon K, Bates, Breanna M, Chiu, Edison Y, Burnett, Madison G, Suarez Gutierrez, Magdalia L, Garcia, Nicolas M, Daman, Andrew W, Greenberg, Philip D

“…Over half of patients diagnosed with high grade serous ovarian cancer will die within five years, highlighting the need for therapy innovation. Engineering T…”
Get full text

Abstract 4980: Engineering adoptive T cell therapy for efficacy in ovarian cancer by Anderson, Kristin G., Bates, Breanna M., Chiu, Edison Y., Greenberg, Philip D.

“…Over 20,000 women are diagnosed with ovarian cancer annually - more than half will die within 5 years and this rate has changed very little in the last 20…”
Get full text

Abstract NTOC-078: ENGINEERING ADOPTIVE T CELL THERAPY FOR EFFICACY IN OVARIAN CANCER by Anderson, Kristin G., Bates, Breanna M., Chiu, Edison Y., Greenberg, Philip D.

“…Over 20,000 women are diagnosed with ovarian cancer annually—more than half will die within 5 years and this rate has changed very little in the last 20 years,…”
Get full text

Engineering adoptive T cell therapy for efficacy in ovarian cancer by Anderson, Kristin G, Bates, Breanna M., Chiu, Edison Y., Greenberg, Philip D.

“…Over 20,000 women are diagnosed with ovarian cancer annually; more than half will die within 5 years, which has changed little over the last 20 years. One…”
Get full text

A mouse model of MYCN-driven retinoblastoma reveals MYCN-independent tumor reemergence by Wu, Nan, Jia, Deshui, Bates, Breanna, Basom, Ryan, Eberhart, Charles G, MacPherson, David

“…The most frequent focal alterations in human retinoblastoma are mutations in the tumor-suppressor gene retinoblastoma (RB) and amplification of the oncogene…”
Get full text

Abstract 3208: Using T cell engineering plus triple checkpoint blockade to enhance the efficacy of adoptive immunotherapy in ovarian cancer by Anderson, Kristin G., Burnett, Madison G., Voillet, Valentin, Chiu, Edison Y., Bates, Breanna M., Garcia, Nicolas M., Gottado, Raphael, Greenberg, Philip D.

“…Over 20,000 women are diagnosed with ovarian cancer in the United States annually, and over half will die within 5 years. Outcomes have changed little in the…”
Get full text

T cell therapy targeting oncogenic antigens in ovarian cancer by Anderson, Kristin G, Bates, Breanna M., Chiu, Edison Y., Greenberg, Philip D.

“…Over 20,000 women are diagnosed with ovarian cancer annually, and more than half will die within 5 years. This rate has changed very little in the last 20…”
Get full text

Abstract B084: Triple checkpoint blockade, but not anti-PD1 alone, enhances the efficacy of engineered adoptive T cell therapy in advanced ovarian cancer by Anderson, Kristin G., Su, Yapeng, Burnett, Madison G., Bates, Breanna M., Rodgers Suarez, Magdalia L., Ruskin, Susan L., Voillet, Valentin, Gottardo, Raphael, Greenberg, Philip D.

“…Background: Over 20,000 women are diagnosed with ovarian cancer annually, and more than half will die within 5 years. This rate has changed little in the last…”
Get full text

Abstract 3608: Triple checkpoint blockade, but not anti-PD1 alone, enhances the efficacy of engineered adoptive T cell therapy in advanced ovarian cancer by Anderson, Kristin G., Su, Yapeng, Burnett, Madison G., Bates, Breanna M., Suarez, Magdalia L. Rodgers, Ruskin, Susan L., Vakil, Aesha, Voillet, Valentin, Gottardo, Raphael, Greenberg, Philip

“…Background: Less than half of ovarian cancer patients survive five years after diagnosis. This rate has changed little in the last 30 years, highlighting the…”
Get full text